DE

The Future Map · technological enabler · active

Vaccine Platforms & Antimicrobials

Maturity

capability 4 / 5

deployment 3 / 5 ← sets the score

absorption 3 / 5 ← sets the score

Bound by incentives · trend deteriorating.

Basis, source, vintage

Vaccine platforms are demonstrably mature; the antimicrobial half is a market failure with a thin pipeline. The score is the blend and the halves must be written separately.

Source: WHO, Antibacterial agents in clinical and preclinical development, 14 Jun 2024 (cutoff 31 Dec 2023): 97 products in clinical development, only 3 in pre-registration. Post-approval insolvencies: Achaogen Ch.11 Apr 2019 (Zemdri approved Jun 2018, ~$800k revenue by end-2018, assets sold $16m against ~$300m development cost), Aradigm Feb 2019, Melinta Dec 2019 (2023–2024)

What it is

Rapid-response vaccine technologies and the development of new classes of antibiotic and antimicrobial agent.

What it does

It is the enabler standing between a pathogen and a pandemic, and between antimicrobial resistance and a return to pre-antibiotic medicine. Its two halves are moving in opposite directions.

Common misconception

That vaccine platform success implies antimicrobial success. Vaccines had a demonstrated pandemic response; the antibiotic pipeline is nearly empty, and for market reasons rather than scientific ones.

Steepens

A megatrend runs at the pace of its shallowest enabler. Marginal links are shown but never set the pace.

What would change its gradient

Shares megatrends with

In the book

Why the Future Arrives Unevenly — Ch. 9 — The Closing of the Planetary Envelope · Ch. 12 — Reading the Ramp

Sources


See it in the map →

Cite this entry

Talin, B. (2026). Vaccine Platforms & Antimicrobials. The Future Map, dataset v0.4.0 (2026-09-07). https://futuremap.talin.digital/e/vaccine-platforms-and-antimicrobials/

Machine view: This entry as Markdown · The whole map as JSON

Updated 2026-09-02.